Pancreatic Adenocarcinoma Metastatic Withdrawn Phase 1 / 2 Trials for Oxaliplatin (DB00526)

Also known as: Metastatic Pancreatic Adenocarcinoma / Pancreatic carcinoma metastatic

IndicationStatusPhase
DBCOND0060224 (Pancreatic Adenocarcinoma Metastatic)Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02575508Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic CancerTreatment